Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma C Morris

Blood

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Blood|May 22, 2025
Haploidentical HSCT: more curative options for patients with CGDEmma C Morris
Blood|January 20, 2018
Editing gene engineering to enhance functionEmma C Morris
Blood|September 4, 2020
HCT for CGD? Yes, and the sooner the betterEmma C Morris
Blood|June 2, 2021
How I use allogeneic HSCT for adults with inborn errors of immunitySiobhan O Burns, Emma C Morris
Blood|May 22, 2016
Optimizing T-cell receptor gene therapy for hematologic malignanciesEmma C Morris, Hans J Stauss
Blood|May 25, 2011
Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigenSharyn Thomas, Shao-An Xue, Charles R M Bangham, et al.
Blood|June 18, 2002
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimenKarl S Peggs, Emma C Morris, Panos D Kottaridis, et al.
Blood|March 8, 2003
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris, Peppy Rebello, Kirsty J Thomson, et al.
Blood|October 25, 2003
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responsesKarl S Peggs, Kirsty Thomson, Daniel P Hart, et al.
Blood|March 31, 2011
Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccinationConstandina Pospori, Shao-An Xue, Angelika Holler, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Blood|May 22, 2025
Haploidentical HSCT: more curative options for patients with CGDEmma C Morris
Blood|January 20, 2018
Editing gene engineering to enhance functionEmma C Morris
Blood|September 4, 2020
HCT for CGD? Yes, and the sooner the betterEmma C Morris
Blood|June 2, 2021
How I use allogeneic HSCT for adults with inborn errors of immunitySiobhan O Burns, Emma C Morris
Blood|May 22, 2016
Optimizing T-cell receptor gene therapy for hematologic malignanciesEmma C Morris, Hans J Stauss
Blood|May 25, 2011
Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigenSharyn Thomas, Shao-An Xue, Charles R M Bangham, et al.
Blood|June 18, 2002
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimenKarl S Peggs, Emma C Morris, Panos D Kottaridis, et al.
Blood|March 8, 2003
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris, Peppy Rebello, Kirsty J Thomson, et al.
Blood|October 25, 2003
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responsesKarl S Peggs, Kirsty Thomson, Daniel P Hart, et al.
Blood|March 31, 2011
Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccinationConstandina Pospori, Shao-An Xue, Angelika Holler, et al.
Pageof 2